Combination Anticonvulsant-Antidepressant Tx Superior to Monotherapy in FM

Share this content:
Pain interference with enjoyment of life was also found to be significantly lower for the combination therapy and duloxetine monotherapy vs placebo.
Pain interference with enjoyment of life was also found to be significantly lower for the combination therapy and duloxetine monotherapy vs placebo.

A randomized controlled trial comparing the efficacy of combined antidepressant and anticonvulsant therapy versus monotherapy for the treatment of fibromyalgia (FM) suggests that combination therapy safely improves outcomes, as measured by pain relief and physical function, according to a recent study published in Pain.

TRENDING ON CPA: Rethinking Strong Opioids for Noncancer Pain

A total of 39 patients received maximally tolerated doses (MTD) of placebo, pregabalin, duloxetine and pregabalin-duloxetine combination for 6 weeks. The primary outcome was average pain intensity over the past 24 hours, rated each morning and averaged over 7 days at MTD. 

Secondary outcomes included worst pain intensity over the past 24 hours and average nocturnal pain intensity during sleeping hours, both rated each morning upon arising and averaged over 7 days at MTD.

Pain with the combination of pregabalin-duloxetine was found to be lower than with placebo (P<.001) and pregabalin alone (P<.001). Pain with duloxetine was lower than placebo (P<0.001) and pregabalin alone (P=.003). The trends which displayed superiority of the combination over duloxetine monotherapy failed to reach significance, though superiority of the combination to duloxetine cannot be ruled out, as the interim analysis indicted a conditional probability of 70% for a significant difference and sample number was limited.

 

Interestingly, the comparison of the combination to duloxetine resulted in a p-value of 0.09. Secondary analyses of percentage change indicated greater reduction (percentage change ± SEM) with combination (27.5% ± 6.0) vs. pregabalin (1.4% ± 5.6, P=.01) and placebo (-7.1% ± 5.5, P=.003).

Concerning the secondary outcomes, patients reported pain relief at MTD of 18.4% on placebo, 38.5% on pregabalin, 41.7% on duloxetine and 67.7% on the pregabalin-duloxetine combination. The worst pain experienced with the combination was lower than both placebo and pregabalin. Pain interference with enjoyment of life was also found to be significantly lower for the combination and duloxetine use vs. placebo.

Summary and Clinical Applicability

A combination of the anticonvulsant pregabalin and the antidepressant duloxetine may help improve pain relief, physical function, and overall quality of life in patients with FM.

Although the benefits of this combination may come with increased risk of drowsiness, the authors conclude that "combining pregabalin with duloxetine for fibromyalgia improves multiple clinical outcomes versus monotherapy." 

Reference

Gilron I, Chaparro LE, Tu D, et al. Combination of pregabalin with duloxetine for fibromyalgia: A randomized controlled trial. Pain. 2016. Publish Ahead of Print DOI: 10.1097/j.pain.0000000000000558.

You must be a registered member of Clinical Pain Advisor to post a comment.